EGFR and non-small cell lung carcinoma: In our clinical case number 4, we used a PCR-based method (COBAS®EGFR test v2 (Roche®)), that was approved by the FDA in 2016 as the first test for the identification of NSCLC patients harboring EGFR mutations in cfDNA from plasma for TKI treatment selection.